Your browser doesn't support javascript.
Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients.
Ruetsch, Caroline; Brglez, Vesna; Crémoni, Marion; Zorzi, Kévin; Fernandez, Céline; Boyer-Suavet, Sonia; Benzaken, Sylvia; Demonchy, Elisa; Risso, Karine; Courjon, Johan; Cua, Eric; Ichai, Carole; Dellamonica, Jean; Passeron, Thierry; Seitz-Polski, Barbara.
  • Ruetsch C; Laboratoire d'Immunologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
  • Brglez V; Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, Université Côte d'Azur, Nice, France.
  • Crémoni M; Unité de Recherche Clinique de la Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
  • Zorzi K; Unité de Recherche Clinique de la Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
  • Fernandez C; Unité de Recherche Clinique de la Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
  • Boyer-Suavet S; Unité de Recherche Clinique de la Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
  • Benzaken S; Unité de Recherche Clinique de la Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
  • Demonchy E; Laboratoire d'Immunologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
  • Risso K; Service d'Infectiologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
  • Courjon J; Service d'Infectiologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
  • Cua E; Service d'Infectiologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
  • Ichai C; Service d'Infectiologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
  • Dellamonica J; Service de réanimation, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
  • Passeron T; Unité de Recherche Clinique de la Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
  • Seitz-Polski B; Service de réanimation, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d'Azur, Nice, France.
Front Med (Lausanne) ; 7: 603961, 2020.
Article in English | MEDLINE | ID: covidwho-1083700
ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan in December 2019 and has since spread across the world. Even though the majority of patients remain completely asymptomatic, some develop severe systemic complications. In this prospective study we compared the immunological profile of 101 COVID-19 patients with either mild, moderate or severe form of the disease according to the WHO classification, as well as of 50 healthy subjects, in order to identify functional immune factors independently associated with severe forms of COVID-19. Plasma cytokine levels, and cytokine levels upon in vitro non-specific stimulation of innate and adaptive immune cells, were measured at several time points during the course of the disease. As described previously, inflammatory cytokines IL1ß, IL6, IL8, and TNFα associated with cytokine storm were significantly increased in the plasma of moderate and severe COVID-19 patients (p < 0.0001 for all cytokines). During follow-up, plasma IL6 levels decreased between the moment of admission to the hospital and at the last observation carried forward for patients with favorable outcome (p = 0.02148). After in vitro stimulation of immune cells from COVID-19 patients, reduced levels of both type I and type II interferons (IFNs) upon in vitro stimulation were correlated with increased disease severity [type I IFN (IFNα) p > 0.0001 mild vs. moderate and severe; type II IFN (IFNγ) p = 0.0002 mild vs. moderate and p < 0.0001 mild vs. severe] suggesting a functional exhaustion of IFNs production. Stimulated IFNα levels lower than 2.1 pg/ml and IFNγ levels lower than 15 IU/mL at admission to the hospital were associated with more complications during hospitalization (p = 0.0098 and p =0.0002, respectively). A low IFNγ level was also confirmed by multivariable analysis [p = 0.0349 OR = 0.98 (0.962; 0.999)] as an independent factor of complications. In vitro treatment with type IFNα restored type IFNγ secretion in COVID-19 patients while the secretion of pro-inflammatory cytokines IL6 and IL1ß remained stable or decreased, respectively. These results (a) demonstrate a functional exhaustion of both innate and adaptive immune response in severe forms of COVID-19; (b) identify IFNα and IFNγ as new potential biomarkers of severity; and (c) highlight the importance of targeting IFNs when considering COVID-19 treatment in order to re-establish a normal balance between inflammatory and Th1 effector cytokines.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Front Med (Lausanne) Year: 2020 Document Type: Article Affiliation country: Fmed.2020.603961

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: Front Med (Lausanne) Year: 2020 Document Type: Article Affiliation country: Fmed.2020.603961